{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:56:40Z","timestamp":1785430600375,"version":"3.56.0"},"reference-count":30,"publisher":"MJH Life Sciences","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"abstract":"<jats:p>Objective: Immunotherapy combined with chemotherapy is a standard treatment for advanced non\u2013small cell\nlung cancer (NSCLC). However, the comparative efficacy and safety of cost-efficient modified PD-1 inhibitors remain incompletely\ncharacterized. This study aimed to determine the optimal choice for the 3 most commonly used modified PD-1 inhibitors\u2014\ntislelizumab, sintilimab, and camrelizumab\u2014combined with chemotherapy in locally advanced or metastatic NSCLC.\nMaterials and methods: We conducted a retrospective study of patients with NSCLC who received chemotherapy plus 1 of\nthe modified PD-1 inhibitors. The primary objective was to compare survival and therapeutic responses across groups. The\nsecondary objective was to analyze adverse events in each group.\nResults: No significant differences were observed in median progression-free survival (PFS) or overall survival across the\n3 groups. However, PD-L1\u2013positive patients (tumor proportion score \u2265 1%) demonstrated significantly prolonged PFS with\ntislelizumab (P = .038) and sintilimab (P = .031) vs camrelizumab. The incidence of immune-related adverse events did not differ\nstatistically across treatments.\nConclusion: Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and\nsintilimab showed superior PFS in PD-L1\u2013positive subgroups, suggesting biomarker-driven therapeutic selection. These findings\nunderscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical\ninsights for personalized treatment strategies.\nKeywords: NSCLC, tislelizumab, sintilimab, camrelizumab, PD-L1<\/jats:p>","DOI":"10.46883\/2026.25921065","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:08:45Z","timestamp":1775239725000},"page":"123","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer"],"prefix":"10.46883","volume":"40","author":[{"given":"Dapeng","family":"Wu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jqapy19","id-type":"ROR","asserted-by":"publisher"}],"name":"Qingdao Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Cui","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jqapy19","id-type":"ROR","asserted-by":"publisher"}],"name":"Qingdao Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhum","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/026e9yy16","id-type":"ROR","asserted-by":"publisher"}],"name":"Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jqapy19","id-type":"ROR","asserted-by":"publisher"}],"name":"Qingdao Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/026e9yy16","id-type":"ROR","asserted-by":"publisher"}],"name":"Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25947","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tWang L, Xian X, Ke H, Wang K. Immunotherapy in EGFR-mutant non-small cell lung cancer. Clin Exp Med. 2025;26(1):10. DOI: 10.1007\/s10238-025-01927-1","DOI":"10.1007\/s10238-025-01927-1"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tRizzo A, Mollica V, Marchetti A, et al. Adjuvant PD-1 and PD-L1 inhibitors and relapse-free survival in cancer patients: the MOUSEION-04 study. Cancers (Basel). 2022;14(17):4142. doi:10.3390\/cancers14174142","DOI":"10.3390\/cancers14174142"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tFranchi M, Pellegrini G, Corrao G. Effectiveness and cost-effectiveness profile of second-line treatments with nivolumab, pembrolizumab and atezolizumab in patients with advanced non-small cell lung cancer. Pharmaceuticals (Basel). 2022;15(4):489. doi:10.3390\/ph15040489","DOI":"10.3390\/ph15040489"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tEisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tFreites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90-92. doi:10.1016\/j.ad.2019.05.009","DOI":"10.1016\/j.adengl.2019.05.021"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tLuo X, Zhou Z, Zeng X, Liu Q. The cost-effectiveness of tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer. Front Pharmacol. 2022;13:935581. doi:10.3389\/fphar.2022.935581","DOI":"10.3389\/fphar.2022.935581"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tLi T, Chen C, Liu L, et al. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative. Cancer Med. 2024;13(3):e7024. doi:10.1002\/cam4.7024","DOI":"10.1002\/cam4.7024"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tGeng Z, Hao B, Geng Q. Tislelizumab: a modified antitumor programmed death receptor 1 antibody. Cancer Control. 2022;29:10732748221111296. doi:10.1177\/10732748221111296","DOI":"10.1177\/10732748221111296"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tHong Y, Feng Y, Sun H, et al. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021;11(3):782-792. doi:10.1002\/2211-5463.13102","DOI":"10.1002\/2211-5463.13102"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tLu S, Wang J, Yu Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16(9):1512-1522. doi:10.1016\/j.jtho.2021.05.005","DOI":"10.1016\/j.jtho.2021.05.005"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tLiu SYM, Zhou Q, Yan HH, et al. Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non\u2013small cell lung cancer: results from phase 2, randomized clinical trial (CTONG1901). J Clin Oncol. 2022;40(suppl 16):9032. doi:10.1200\/JCO.2022.40.16_suppl.9032","DOI":"10.1200\/JCO.2022.40.16_suppl.9032"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tWang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 2019;11(8):1443-1451. doi:10.1080\/19420862.2019.1654303","DOI":"10.1080\/19420862.2019.1654303"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tZhang S, Zhang M, Wu W, et al. Preclinical characterization of sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antib Ther. 2018;1(2):65-73. doi:10.1093\/abt\/tby005","DOI":"10.1093\/abt\/tby005"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tLiu SYM, Huang J, Deng JY, et al. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): a phase 2, randomized, controlled trial. Sci Bull (Beijing). 2024;69(4):535-543. doi:10.1016\/j.scib.2023.12.046","DOI":"10.1016\/j.scib.2023.12.046"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tYang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636-1646. doi:10.1016\/j.jtho.2020.07.014","DOI":"10.1016\/j.jtho.2020.09.028"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tZhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501-1511. doi:10.1016\/j.jtho.2021.04.011","DOI":"10.1016\/j.jtho.2021.04.011"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tZhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced nonsquamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305-314. doi:10.1016\/S2213-2600(20)30365-9","DOI":"10.1016\/S2213-2600(20)30365-9"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tLiu K, Tan S, Jin W, et al. N-glycosylation of PD-1 promotes binding of camrelizumab. EMBO Rep. 2020;21(12):e51444. doi:10.15252\/embr.202051444","DOI":"10.15252\/embr.202051444"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tXu CR, Chen Q, Zhou C, et al. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV). Transl Lung Cancer Res. 2023;12(1):127-140. doi:10.21037\/tlcr-22-852","DOI":"10.21037\/tlcr-22-852"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tRen S, Chen J, Xu X, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol. 2022;17(4):544-557. doi:10.1016\/j.jtho.2021.11.018","DOI":"10.1016\/j.jtho.2021.11.018"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tRizzo A, Dall\u2019Olio FG, Altimari A, Giunchi F, Ardizzoni A. Role of PD-L1 assessment in advanced NSCLC: does it still matter? Anticancer Drugs. 2021;32(10):1084-1085. doi:10.1097\/CAD.0000000000001118","DOI":"10.1097\/CAD.0000000000001118"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tAlex F, Alfredo A. Promising predictors of checkpoint inhibitor response in NSCLC. Expert Rev Anticancer Ther. 2020;20(11):931-937. doi:10.1080\/14737140.2020.1816173","DOI":"10.1080\/14737140.2020.1816173"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tFriedlaender A, Metro G, Signorelli D, et al. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score\u2009\u226550% treated with front-line pembrolizumab. Acta Oncol. 2020;59(9):1058-1063. doi:10.1080\/0284186X.2020.1781249","DOI":"10.1080\/0284186X.2020.1781249"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tMollica V, Rizzo A, Marchetti A, et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med. 2023;23(8):5039-5049. doi:10.1007\/s10238-023-01159-1","DOI":"10.1007\/s10238-023-01159-1"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tDall\u2019Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status\u2009\u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-a systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95-104. doi:10.1016\/j.lungcan.2020.04.027","DOI":"10.1016\/j.lungcan.2020.04.027"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tAuclin E, Benitez-Montanez J, Tagliamento M, et al. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. Lung Cancer. 2023;178:116-122. doi:10.1016\/j.lungcan.2023.02.002","DOI":"10.1016\/j.lungcan.2023.02.002"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tSahin TK, Ayasun R, Rizzo A, Guven DC. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers (Basel). 2024;16(21):3689. doi:10.3390\/cancers16213689","DOI":"10.3390\/cancers16213689"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tGuven DC, Sahin TK, Erul E, et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Mol Biosci. 2022;9:1039121. doi:10.3389\/fmolb.2022.1039121","DOI":"10.3389\/fmolb.2022.1039121"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tGuven DC, Erul E, Kaygusuz Y, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624. doi:10.1007\/s00520-023-08083-w","DOI":"10.1007\/s00520-023-08083-w"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tLi A, Wang Y, Yu Z, et al. STK11\/LKB1-deficient phenotype rather than mutation diminishes immunotherapy efficacy and represents STING\/type I interferon\/CD8+\u2009T-cell dysfunction in NSCLC. J Thorac Oncol. 2023;18(12):1714-1730. doi:10.1016\/j.jtho.2023.07.020","DOI":"10.1016\/j.jtho.2023.07.020"}],"container-title":["ONCOLOGY"],"original-title":[],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:08:52Z","timestamp":1775239732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/comparison-of-the-3-most-commonly-used-modified-pd-1-inhibitors-plus-chemotherapy-in-inoperable-wild-type-non-small-cell-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.46883\/2026.25921065","relation":{},"ISSN":["0890-9091","2767-7389"],"issn-type":[{"value":"0890-9091","type":"print"},{"value":"2767-7389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}